Lewy Body Dementia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lewy Body Dementia – Drugs In Development, 2024 report and make more profitable business decisions.
Lewy body dementia (LBD) is a progressive neurodegenerative disorder characterized by the abnormal accumulation of alpha-synuclein protein deposits (Lewy bodies) in the brain. This condition shares similarities with both Alzheimer’s disease and Parkinson’s disease, presenting a complex spectrum of symptoms that affect cognition, movement, behavior, and autonomic functions. LBD manifests through various symptoms that may fluctuate in severity, including cognitive changes (impaired thinking, attention, and visual-spatial abilities); fluctuating attention and alertness; visual hallucinations, often detailed and recurrent; motor symptoms (Parkinsonism, such as stiffness, slowness, tremors, and gait disturbances); and sleep disturbances, including REM sleep behavior disorder (acting out dreams).
The Lewy Body Dementia drugs in development market research report provide comprehensive information on the therapeutics under development for Lewy Body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lewy Body Dementia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lewy Body Dementia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 46 molecules, with 45 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lewy Body Dementia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lewy Body Dementia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lewy Body Dementia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AC Immune SAAccure Therapeutics SL
AFFiRiS AG
Alkermes Plc
Annovis Bio Inc
Aprinoia Therapeutics Inc
AptaBio Therapeutics Inc
AriBio Co Ltd
Asceneuron SA
Athira Pharma Inc
Bioasis Technologies Inc
BRI Pharma Co Ltd
CervoMed Inc
CLAIRIgene LLC
Cognition Therapeutics Inc
CuraSen Therapeutics Inc
Denali Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Immungenetics AG
Inhibikase Therapeutics Inc
Johnson & Johnson
KeifeRx LLC
Kineta Inc
medilabo RFP Inc
NLS Pharmaceutics AG
NurrOn Pharmaceuticals Inc
Oryzon Genomics SA
Parkure Ltd
ProMIS Neurosciences Inc
Samus Therapeutics Inc
Sinfonia Biotherapeutics Inc
Sun Pharma Advanced Research Company Ltd
University of Florida
Vanqua Bio Inc
Vaxxinity Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lewy Body Dementia reports